Zusammenfassung
Urologika werden zur Behandlung von Miktionsstörungen im weitesten Sinne angewandt, denen Erkrankungen der Prostata, Harnwegsinfektionen und verschiedene andere urologische Störungen zugrundeliegen können. 1999 gehörten 60 Präparate dieser Indikationsgruppe zu den 2500 meistverordneten Arzneimitteln (Tabelle 47.1). Wie in den vergangenen Jahren sind die Verordnungen 1999 in der gesamten Indikationsgruppe zurückgegangen, allerdings haben sich die Umsätze nur wenig verändert. Die Verordnungen von Prostatamitteln aus der Gruppe der AlpharRezeptorenblocker und der 5?-Reduktasehemmer haben als einzige Arzneimittelgruppe zugenommen, während alle anderen Gruppen rückläufig waren, insbesondere die pflanzlichen Prostatamittel, die in ihrem therapeutischen Wert ungesichert sind (Abbildung 47.1).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abrams P., Freeman R., Anderström C., Mattiasson A. (1998): Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br. J. Urol. 81: 801–810.
Berges R.R., Windeler H., Trampisch HJ., Senge T. and the β-sitosterol study group (1995): Randomised, placebo-controlled, double-blind clinical trial of ?-sitosterol in patients with benign prostatic hyperplasia. Lancet 345: 1529–1532.
Bergogne-Berezin E., Berthelot G., Muller-Serieys C. (1987): Present status of nitroxoline. Pathol. Biol. (Paris) 35: 873–878.
Bhatia N.N., Karram M.M., Bergman A., Evans R.P. (1992): Antibiotic prophylaxis following lower urinary tract instrumentation. Urology 39: 583–585.
Boyle P., Gould A.L., Roehrborn C.G. (1996): Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48: 398–405.
Bundesgesundheitsamt (1994): Aufbereitungsmonographie Uvae ursi folium (Bärentraubenblätter). Bundesanzeiger Nr. 109, S. 6213, 15.6.1994.
Burgio K.L., Locher J.L., Goode P.S., Hardin J.M., McDowell BJ. et al. (1998): Behavioral vs drug treatment for urge urinary incontinence in older women. A randomized controlled trial. JAMA 280: 1995–2000.
Caine M., Raz S., Ziegler M. (1975): Adrenergic and cholinergic receptors in the human prostate, prostatic capsule, and bladder neck. Brit. J. Urol. 27: 193–202.
Chappie C.R. (1996): Selective ?1adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur. Urol. 29: 129–144.
Chappie C.R. (2000): Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(5A Suppl.): 33–46.
Cobb M.M., Salen G., Tint G.S. (1997): Comparative effect of dietary sitosterol on plasma sterols and cholesterol and bile acid synthesis in a sitosterolemic homozygote and heterozygote subject. J. Am. Coll. Nutr. 16: 605–613.
Coraggio M.J., Gross T.P., Roscelli J.D. (1989): Nitrofurantoin toxicity in children. Pediatr. Infect. Dis. J. 8: 163–166.
Drutz H.P., Appell R.A., Gleason D., Klimberg I., Radomski S. (1999): Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int. Urogynecol. J. 10: 283–289.
Editorial (1988): Medical treatment of benign prostatic hyperplasia. Lancet I: 1083–1084.
Expertengruppe und Arbeitskreis BPH (1999): Leitlinien der Deutschen Urologen zur Therapie des BPH-Syndroms. Urologe (A) 38: 529–536.
Flanigan R.C., Reda DJ., Wasson J.H., Anderson R.J., Abdellatif M., Bruskewitz R.C. (1998): 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J. Urol. 160: 12–16.
Foglar R., Shibata K., Horie K., Hirasawa A., Tsujimoto G. (1995): Use of recombinant ?1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur. J. Pharmacol. 288: 201–207.
Goepel M., Hecker U., Krege S., Rubben H., Michel M.C. (1999): Saw palmetto extracts potently and noncompetitively inhibit human alpha1adrenoceptors in vitro. Prostate 38: 208–215.
Grasso M., Montesano A., Buonaguidi A., Castelli M., Lania C. et al. (1995): Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. Arch. Esp. Urol. 48: 97–103.
Guay D.R.P. (1999): Tolterodine, a new antimuscarinic drug for treatment of bladder overactivity. Pharmacotherapy 19: 267–280.
Hadorn D.C., Baker D., Hodges J.S., Hicks N. (1996): Rating the quality of evidence for clinical practice guidelines. J Clin. Epidemiol. 49: 749–754.
Iselin C.E., Schmidlin F., Borst E, Rohner S., Graber P. (1997): Oxybutynin in the treatment of early detrusor instability after transurethral resection of the prostate. Brit. J. Urol. 79: 915–919.
Johnson H.W., Anderson J.D., Chambers G.K., Arnold W.J., Irwin B.J., Brinton J.R. (1994): A short-term study of nitrofurantoin prophylaxis in children managed with clean intermittent catheterization. Pediatrics 93: 752–755.
Klippel K.F., Hiltl D.M., Schipp B. (1997): A multicentric, placebo-controlled, double-blind clinical trial of ?-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Brit. J. Urol. 80: 427–432.
Larsson G., Hallén B., Nilvebrant L. (1999): Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 53: 990–998.
Lepor H., Williford W.O., Barry M.J., Brawer M.K., Dixon C.M. et al. (1996): The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. N. Engl. J. Med. 335: 533–539.
Lowe EC., Dreikorn K., Borkowski A., Braeckman J., Denis L. et al. (1998): Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH. Prostate 37: 187–193.
Malinverni R., Hoigné R., Sonntag R. (1996): Sulfonamides, other folic acid antagonists and miscellaneous antibacterial drugs. In: Dukes M.N.G. (ed.): Meyler’s side effects of drugs. 13th ed. Elsevier, Amsterdam Lausanne New York Oxford Shannon Tokyo, pp. 843–871.
Millard R., Tuttle J., Moore K., Susset J., Clarke B., Dwyer P., Davis B.E. (1999): Clinical efficacy and safety of tolterodine compared to placebo in detrusor over-activity. J. Urol. 161: 1551–1555.
Moore K.H., Hay D.M., Imrie A.E., Watson A., Goldstein M. (1990): Oxybutynin hydrochloride (3 mg) in the treatment of women with idiopathic detrusor instability. Brit. J. Urol. 66: 479–485.
Nilvebrant L., Hallen B., Larsson G. (1997): Tolterodine, a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data. Life Sci. 60: 1129–1136.
Ouslander J.G., Blaustein J., Connor A., Pitt A. (1988): Habit training and oxybutynin for incontinence in nursing home patients: a placebo-controlled trial. J. Am. Geriatr. Soc. 36: 40–46.
Ouslander J.G., Schnelle J.E, Uman G., Fingold S., Nigam J.G. et al. (1995): Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J. Am. Geriatr. Soc. 43: 610–617.
Rentzhog L., Stanton S.L., Clardozo L., Nelson E., Fall M., Abrams P. (1998): Efficacy and safety of tolterodine in patients with detrusor instability: a doseranging study. Br. J. Urol. 81: 42–48.
Riva D., Casolati E. (1984): Oxybutynin chloride in the treatment of female idiopathic bladder instability. Results from double blind treatment. Clin. Exp. Obst. Gyn. 11: 37–42.
Schlager T.A., Anderson S., Trudell J., Hendley J.O. (1998): Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization. J. Pediatr. 132: 704–708.
Simon C., Stille W. (2000): Antibiotika-Therapie in Klinik und Praxis. 10. Aufl., Schattauer, Stuttgart New York, S. 238–241, 247–252.
Snyder R., Witz G., Goldstein B.D. (1993): The toxicology of benzene. Environ. Health Perspect. 100: 293–306.
Stamm W.E., Counts G.W., Wagner K.F., Martin D., Gregory D. et al. (1980): Antimicrobial prophylaxis of recurrent urinary tract infections: a double-blind, placebo-controlled trial. Ann. Intern. Med. 92: 770–775.
Stöhrer M., Bauer P., Giannetti B.M., Richter R., Burgdörfer H., Mürtz G. (1991): Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. Urol. Int. 47: 138–143.
Szonyi G., Collas D.M., Ding Y.Y., Malone-Lee J.G. (1995): Oxybutynin with bladder retraining for detrusor instability in elderly people: a randomized controlled trial. Age Ageing 24: 287–291.
Tapp A.J.S., Cardozo L.D., Versi E., Cooper D. (1990): The treatment of detrusor instability in postmenopausal women with oxyxbutynin chloride: a double blind placebo controlled study. Brit. J. Obstet. Gynaec. 97: 521–526.
Thiiroff J.W., Bunke B., Ebner A., Faber P., de Geeter P. et al. (1991): Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo. J. Urol. 145: 813–817.
Thüroff J.W, Chartier-Kastler E., Corcus J., Humke J., Jonas U. et al. (1998): Medical treatment and medical side effects in urinary incontinence in the elderly. World J. Urol. 16 (suppl): S48–S61.
Uhari M., Nuutinen M., Turtinen J. (1996): Adverse reactions in children during long-term antimicrobial therapy. Pediatr. Infect. Dis. 15: 404–418.
Van Kerrebroeck P.E.V.A., Amarenco G,. Thüroff J.W., Madersbacher H.G., Lock M.T.W.T., Messelink E.J., Soler J.M. (1998): Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol. Urodynam. 17: 499–512.
Wehnert J., Sage S. (1992): Therapie der Blaseninstabilität und Urge-Inkontinenz mit Propiverin hydrochlorid (Mictonorm®) und Oxybutyninchlorid (Dridase®) —eine randomisierte Cross-over-Vergleichsstudie. Akt. Urol. 23: 7–11.
Wilt T.J., Ishani A., Stark G., MacDonald R., Lau J., Mulrow C. (1998): Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 280: 1604–1609.
Zorzitto M.L., Holliday P.J., Jewett M.A.S., Herschorn S., Fernie G.R. (1989): Oxy-butynin chloride for geriatric urinary dysfunction: a double-blind placebo-controlled study. Age Ageing 18: 195–200.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mühlbauer, B., Oßwald, H. (2001). Urologika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2000. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-56832-9_47
Download citation
DOI: https://doi.org/10.1007/978-3-642-56832-9_47
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-67573-0
Online ISBN: 978-3-642-56832-9
eBook Packages: Springer Book Archive